Search
Supernus Pharmaceuticals Inc
SUPNAdd to Watchlist
46.370USD
-0.140-0.30%
Market hours （ET）Quotes delayed by 15 min
2.69BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.30%
5 Days
+4.25%
1 Month
+0.41%
6 Months
-6.70%
Year to Date
-6.70%
1 Year
+47.11%
Key Figures
46.980Open
47.360High
336.62KVolume
LossP/E TTM
10.10P/E Dynamic
--Dividend TTM
0.58%Turnover Ratio
46.510Prev. Close
45.990Low
11.39MTurnover
36.44P/E Static
2.50P/B
0.00%Div Yield TTM
-2.04%ROA
59.68052wk High
0.35Volume Ratio
73.86MNet Profit
58.04MShares
-0.5110EPS TTM
0.55Beta
-2.75%ROE
30.83052wk Low
2.95%Amplitude
76.39%Gross Margin
2.69BMarket Cap
2.17Reward/Risk
1.80%Risk Rate
TradingKey Stock Score of Supernus Pharmaceuticals Inc
Currency: USD Updated: 2026-06-30Key Insights
Supernus Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 28 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 62.83.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Supernus Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative-
Supernus Pharmaceuticals Inc Highlights
StrengthsRisks
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.34% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -91.02, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 66.06M shares, increasing 0.36% quarter-over-quarter.
Held by Third Avenue Management
Star Investor Third Avenue Management holds 169.17K shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
62.833
Target Price
+34.26%
Upside Space
Supernus Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Supernus Pharmaceuticals Inc Info
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Ticker SymbolSUPN
CompanySupernus Pharmaceuticals Inc
CEOKhattar (Jack A)
Websitehttps://www.supernus.com
Related Instruments
-1.49%
-0.34%
-2.93%
-0.25%
-2.02%
-1.47%
-0.80%
+1.51%
-0.29%
-1.06%
+0.18%
-2.09%
-2.33%
-3.01%
+1.79%
0.00%
+0.24%
-1.95%
+0.33%
-0.62%Popular Instruments
52354.200
+157.900 (+0.30%)
29892.600
-332.000 (-1.10%)
7499.400
+17.000 (+0.23%)
15370.000
-225.000 (-1.44%)
69652.000
-1204.000 (-1.70%)
6279.200
-47.800 (-0.76%)
68.588
-1.333 (-1.91%)
294.515
+5.155 (+1.78%)
197.950
-2.140 (-1.07%)
4061.100
+53.820 (+1.34%)
FAQs
What is the current price of Supernus Pharmaceuticals Inc (SUPN)?
The current price of Supernus Pharmaceuticals Inc (SUPN) is 46.51.
What is the symbol of Supernus Pharmaceuticals Inc?
The ticker symbol of Supernus Pharmaceuticals Inc is SUPN.
What is the 52-week high of Supernus Pharmaceuticals Inc?
The 52-week high of Supernus Pharmaceuticals Inc is 59.68.
What is the 52-week low of Supernus Pharmaceuticals Inc?
The 52-week low of Supernus Pharmaceuticals Inc is 30.83.
What is the market capitalization of Supernus Pharmaceuticals Inc?
The market capitalization of Supernus Pharmaceuticals Inc is 2.70B.
Is Supernus Pharmaceuticals Inc (SUPN) currently rated as Buy, Hold, or Sell?
According to analysts, Supernus Pharmaceuticals Inc (SUPN) has an overall rating of Buy, with a price target of 62.83.
What is the Earnings Per Share (EPS TTM) of Supernus Pharmaceuticals Inc (SUPN)?
The Earnings Per Share (EPS TTM) of Supernus Pharmaceuticals Inc (SUPN) is -0.68.